Wilairat P - Search Results

1

Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.

Jirasomprasert T, Morales NP, Limenta LM, Sirijaroonwong S, Yamanont P, Wilairat P, Fucharoen S, Chantharaksri U. Jirasomprasert T, et al. Among authors: wilairat p. Free Radic Res. 2009 May;43(5):485-91. doi: 10.1080/10715760902870611. Free Radic Res. 2009. PMID: 19353420

2

Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.

Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP. Limenta LM, et al. Among authors: wilairat p. Clin Pharmacokinet. 2011 Jan;50(1):41-50. doi: 10.2165/11536630-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21028920

3

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

Limenta LM, Jirasomprasert T, Tankanitlert J, Svasti S, Wilairat P, Chantharaksri U, Fucharoen S, Morales NP. Limenta LM, et al. Among authors: wilairat p. Br J Clin Pharmacol. 2008 Jun;65(6):908-16. doi: 10.1111/j.1365-2125.2008.03103.x. Epub 2008 Mar 3. Br J Clin Pharmacol. 2008. PMID: 18318774 Free PMC article.

4

Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers.

Morales NP, L, Yamanont P, Jirasomprasert T, Wilairat P, Chantharaksri U, Chuncharunee S, Fucharoen S. Morales NP, et al. Among authors: wilairat p. Int J Clin Pharmacol Ther. 2009 May;47(5):358-64. doi: 10.5414/cpp47358. Int J Clin Pharmacol Ther. 2009. PMID: 19473596 Clinical Trial.

5

Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia : Impact of Splenectomy and Iron Status.

Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP. Limenta LM, et al. Among authors: wilairat p. Clin Pharmacokinet. 2011 Jan;50(1):41-50. doi: 10.2165/11536630-000000000-00000. Clin Pharmacokinet. 2011. PMID: 27975237

6

Quantitative determination of ortho- and meta-tyrosine as biomarkers of protein oxidative damage in beta-thalassemia.

Matayatsuk C, Poljak A, Bustamante S, Smythe GA, Kalpravidh RW, Sirankapracha P, Fucharoen S, Wilairat P. Matayatsuk C, et al. Among authors: wilairat p. Redox Rep. 2007;12(5):219-28. doi: 10.1179/135100007X200272. Redox Rep. 2007. PMID: 17925094

7

Elevated F2-isoprostanes in thalassemic patients.

Matayatsuk C, Lee CY, Kalpravidh RW, Sirankapracha P, Wilairat P, Fucharoen S, Halliwell B. Matayatsuk C, et al. Among authors: wilairat p. Free Radic Biol Med. 2007 Dec 15;43(12):1649-55. doi: 10.1016/j.freeradbiomed.2007.08.026. Epub 2007 Sep 7. Free Radic Biol Med. 2007. PMID: 18037130

8

Tandem measurements of iron and creatinine by cross injection analysis with application to urine from thalassemic patients.

Choengchan N, Mantim T, Inpota P, Nacapricha D, Wilairat P, Jittangprasert P, Waiyawat W, Fucharoen S, Sirankpracha P, Morales NP. Choengchan N, et al. Among authors: wilairat p. Talanta. 2015 Feb;133:52-8. doi: 10.1016/j.talanta.2014.04.090. Epub 2014 Jul 7. Talanta. 2015. PMID: 25435226

9

Molecular basis of beta (0)-thalassemia/HbE disease in Thailand.

Petmitr S, Wilairat P, Kownkon J, Winichagoon P, Fucharoen S. Petmitr S, et al. Among authors: wilairat p. Biochem Biophys Res Commun. 1989 Jul 31;162(2):846-51. doi: 10.1016/0006-291x(89)92387-5. Biochem Biophys Res Commun. 1989. PMID: 2757643

10

No evidence for a role of disulfide bonds in the attachment of inclusion bodies to the red cell membrane.

Pravatmuang P, Fucharoen S, Wilairat P. Pravatmuang P, et al. Among authors: wilairat p. Birth Defects Orig Artic Ser. 1987;23(5A):227-30. Birth Defects Orig Artic Ser. 1987. PMID: 2825830 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page